Tumor Board Review

The most comprehensive clinical case review book in the field. With hands-on input from current fellows and oncologists, this new edition has been enhanced and reformatted for greater efficiency and practicality.

---

Now in its 3rd edition, Tumor Board Review: Evidence-Based Case Reviews and Questions is the most comprehensive clinical case review book in the field. With hands-on input from current fellows and oncologists, this new edition has been enhanced and reformatted for greater efficiency and practicality.


The review covers all disease-site areas in oncology and features a wide variety of board-style questions pivotal in helping fellows and oncologists prepare for both the ABIM medical oncology board exam and maintenance of certification (MOC) assessments. Evidence-based discussions of difficult patient cases offer an in-depth and accurate depiction of what is discussed at tumor boards and foster critical thinking essential for clinical practice. Patient cases also highlight impactful treatment decisions that include newly approved immunotherapies and targeted therapies. Each chapter contains digestible essentials for each case, including a summary of diagnosis, molecular and genomic testing, treatment options, toxicity considerations, follow-up, and survivorship. Each chapter ends with high-yield multiple-choice questions including answers and detailed rationales ensuring readers are well-equipped with the knowledge they need to make well-informed, individualized treatment decisions. Tumor Board Review: Evidence-Based Case Review and Questions is an essential case-based reference for anyone working in oncology.


Key Features:




Describes more than 120 patient cases, including locally advanced and metastatic cases for each major disease site

Contains 300 board-style questions and answers related to case reviews

Includes new advances in diagnosis and therapy, with a greater emphasis on immunotherapies, cancer genomics, and precision-based targeted therapies

Provides essentials for toxicity considerations, follow-up, and survivorship considerations